Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 352,500,096
  • Shares Outstanding, K 2,407,623
  • Annual Sales, $ 85,159 M
  • Annual Income, $ 35,153 M
  • EBIT $ 13,952 M
  • EBITDA $ 21,438 M
  • 60-Month Beta 0.51
  • Price/Sales 4.07
  • Price/Cash Flow 10.53
  • Price/Book 4.94

Options Overview Details

View History
  • Implied Volatility 19.76% ( +1.53%)
  • Historical Volatility 14.46%
  • IV Percentile 94%
  • IV Rank 72.63%
  • IV High 22.48% on 08/05/24
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.60
  • Today's Volume 21,951
  • Volume Avg (30-Day) 31,576
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 379,710
  • Open Int (30-Day) 359,859

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.00
  • Number of Estimates 8
  • High Estimate 2.10
  • Low Estimate 1.94
  • Prior Year 2.29
  • Growth Rate Est. (year over year) -12.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
143.52 +0.86%
on 12/16/24
157.12 -7.87%
on 11/22/24
-10.02 (-6.47%)
since 11/18/24
3-Month
143.52 +0.86%
on 12/16/24
166.75 -13.19%
on 10/15/24
-21.40 (-12.88%)
since 09/18/24
52-Week
143.13 +1.13%
on 04/18/24
168.85 -14.27%
on 09/04/24
-10.69 (-6.88%)
since 12/18/23

Most Recent Stories

More News
Dow on a Record Losing Streak: Should You Buy its ETF?

The Dow Jones Industrial Average has been on its worst losing streak in nearly 50 years as investors continued to rotate out of old economy names and pile into tech stocks and small-caps. The blue-chip...

NVDA : 128.91 (-1.14%)
JNJ : 144.75 (-1.13%)
AMGN : 258.78 (-2.70%)
DIA : 424.22 (-2.61%)
UNH : 499.72 (+2.92%)
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A therapy, duvakitug (formerly TEV’574), for the treatment...

JNJ : 144.75 (-1.13%)
TEVA : 21.20 (+1.53%)
ABBV : 173.02 (-1.35%)
SNY : 47.01 (-3.94%)
The Smartest Dividend Stocks to Buy With $500 Right Now

As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks...

ABT : 111.93 (-1.20%)
KO : 62.85 (-0.87%)
JNJ : 144.75 (-1.13%)
Stock market today: Wall Street trims its stellar gains as Nvidia's star dims again

U.S. stock indexes trimmed some of their stellar gains for the year

MSTR : 349.64 (-9.52%)
NVDA : 128.91 (-1.14%)
AVGO : 223.62 (-6.91%)
BAC : 43.50 (-3.44%)
$SPX : 5,872.16 (-2.95%)
MS : 121.04 (-5.25%)
JNJ : 144.75 (-1.13%)
$IUXX : 21,209.31 (-3.60%)
PFE : 25.89 (-2.04%)
BMY : 56.84 (-1.41%)
BAX : 28.91 (-2.46%)
$DOWI : 42,326.87 (-2.58%)
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease

Eli Lilly LLY announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its IL-23p19 antibody Omvoh (mirikizumab) for expanded use in Crohn’s disease...

JNJ : 144.75 (-1.13%)
LLY : 764.71 (-1.79%)
ABBV : 173.02 (-1.35%)
Insider Purchase: Director at $JNJ (JNJ) Buys 1,000 Shares

MARK A WEINBERGER, a director at $JNJ ($JNJ), bought 1,000 shares of the company on 12-12-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

JNJ : 144.75 (-1.13%)
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over

It's been a banner year for the stock market. However, not every stock has been a winner as some sectors performed better than others. Tech and utilities soared, while others like real estate and healthcare...

ALK : 62.44 (-1.20%)
MRK : 98.34 (-1.72%)
JNJ : 144.75 (-1.13%)
NKE : 76.90 (-1.41%)
$DOWI : 42,326.87 (-2.58%)
AMGN : 258.78 (-2.70%)
BA : 172.62 (-0.24%)
Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year?

When investors look for reliable dividend-paying companies, they typically consider factors such as the track record for paying and raising the dividend over time, if the company is an industry leader,...

KMB : 130.37 (-0.59%)
AAPL : 248.05 (-2.14%)
KO : 62.85 (-0.87%)
MNST : 51.54 (-0.79%)
JNJ : 144.75 (-1.13%)
CL : 92.75 (-0.79%)
LRLCY : 69.7600 (-3.34%)
CLX : 161.72 (-0.98%)
PG : 169.08 (-0.73%)
UL : 57.83 (-2.48%)
KVUE : 21.51 (-2.40%)
PEP : 154.43 (-1.10%)
ISRG Stock Reaches All-Time High: Strength in Uptrend to Continue?

Shares of Intuitive Surgical ISRG touched an all-time high of $552.08 on Dec. 04. Although the share price closed slightly below $547.65 yesterday, it has shown a strong uptrend so far this year, which...

JNJ : 144.75 (-1.13%)
MDT : 80.03 (-1.65%)
ISRG : 526.47 (-3.43%)
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ

This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s...

AZN : 64.64 (-3.78%)
JNJ : 144.75 (-1.13%)
MRK : 98.34 (-1.72%)
LLY : 764.71 (-1.79%)
RHHBY : 34.9100 (-2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 148.17
2nd Resistance Point 147.46
1st Resistance Point 146.10
Last Price 144.75
1st Support Level 144.03
2nd Support Level 143.32
3rd Support Level 141.96

See More

52-Week High 168.85
Fibonacci 61.8% 159.02
Fibonacci 50% 155.99
Fibonacci 38.2% 152.96
Last Price 144.75
52-Week Low 143.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar